CCO Oncology Podcast

189 Folgen

1. HER2-Positive Breast Cancer: Current Approaches for Quality Care

   Vom: 28.7.2022
2. New Evidence With BTK Inhibitor Therapy in CLL and MCL From EHA 2022

   Vom: 21.7.2022
3. New Evidence With BTK Inhibitor Therapy in CLL and MCL From ASCO 2022

   Vom: 6.7.2022
4. Expert Insights on New Data From ASCO 2022 Informing Treatment for Endometrial, Ovarian, and Cervical Cancers

   Vom: 30.6.2022
5. Expert Insight on Key Data From SGO 2022 Informing Treatment for Endometrial, Ovarian, and Cervical Cancers

   Vom: 19.5.2022
6. Call to Action and Reflection: Inclusive, Compassionate, and High-Quality Healthcare for Transgender Individuals

   Vom: 13.5.2022
7. Inclusive Healthcare for Transgender Individuals: Insights From a Healthcare Professional’s Transition Experience

   Vom: 2.5.2022
8. Anti-TIGIT Therapy: Overview of Current Clinical Evidence and Key Ongoing Trials

   Vom: 15.4.2022
9. Targeting TIGIT: Understanding New Approaches for Inhibiting the Immune Checkpoint Pathway

   Vom: 7.4.2022
10. Evolving Treatment Landscape With Regorafenib and TAS-102 in Metastatic Colorectal Cancer

    Vom: 6.4.2022
11. Expert Answers to Key Questions on Current and Emerging BTK Inhibitor Therapies for CLL and MCL

    Vom: 31.3.2022
12. Expert Insights on Optimal Current Management of Patients With Cholangiocarcinoma

    Vom: 21.3.2022
13. Cancer Conversations: 3 Case Challenges of Real Patients With Myelodysplastic Syndromes

    Vom: 14.3.2022
14. Expert Insights on Targeted Therapies for Advanced Systemic Mastocytosis

    Vom: 10.3.2022
15. Advances in B-Cell Lymphomas: Understanding Current Treatment Approaches

    Vom: 25.2.2022
16. TKIs for Advanced HCC in the Second Line and Beyond

    Vom: 22.2.2022
17. New Directions With PARP Inhibitors in Pancreatic Cancer

    Vom: 21.2.2022
18. Evolving Therapy for Myeloma: Experts Discuss Patient Case Examples

    Vom: 18.2.2022
19. Expert Insights on Advances in Immune Thrombocytopenia

    Vom: 7.2.2022
20. Precision Medicine for aTTP: Expert Answers to Your Questions

    Vom: 1.2.2022